DMRA 株価分析 — Damora Therapeutics, Inc. (Healthcare >> Biotechnology)
DMRA に関するよくある質問
DMRAのROE(自己資本利益率)は?
Damora Therapeutics, Inc.のROEは-46.07%です。
DMRAの配当利回りは?
Damora Therapeutics, Inc.の配当利回りは0.00%です。
DMRAの品質スコア(Quality Score)は?
当社のAIはDMRAの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
DMRAは今が買い時ですか?
当社AIのタイミングスコアは100点中89点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
DMRAはどのセクターに属しますか?
Damora Therapeutics, Inc.はHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
DMRA AI Analysis Summary
Our AI summary for DMRA: Damora Therapeutics, Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -46.07%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 30.02
Price
1.46
(5.11%)
Day Change
|
|
|---|
DMRA, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) but テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 82 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 30.02 |
| PBV / Sector |
3.45 / 44,022.72
|
| Earning Per Share | -4.01 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
13.58 M
GREAT
|
| Average 1W Daily Value |
10.13 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:05 |
| Symbol | DMRA |
| Name | DAMORA THERAPEUTICS, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 61.55 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,757.96 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building 23, Waltham, MA, United States, 02453
Phone: 781 281 9020
Website: https://www.damoratx.com
Sector: Healthcare >> Biotechnology
Description: Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google